NL990012I2 - Geneesmiddelen die salmeterol en fluticason bevatten. - Google Patents

Geneesmiddelen die salmeterol en fluticason bevatten.

Info

Publication number
NL990012I2
NL990012I2 NL990012C NL990012C NL990012I2 NL 990012 I2 NL990012 I2 NL 990012I2 NL 990012 C NL990012 C NL 990012C NL 990012 C NL990012 C NL 990012C NL 990012 I2 NL990012 I2 NL 990012I2
Authority
NL
Netherlands
Prior art keywords
fluticasone
medicines containing
salmeterol
containing salmeterol
inhalation
Prior art date
Application number
NL990012C
Other languages
English (en)
Dutch (nl)
Other versions
NL990012I1 (nl
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27264677&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL990012(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB898920392A external-priority patent/GB8920392D0/en
Priority claimed from GB898923644A external-priority patent/GB8923644D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NL990012I1 publication Critical patent/NL990012I1/nl
Publication of NL990012I2 publication Critical patent/NL990012I2/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
NL990012C 1989-09-08 1999-04-14 Geneesmiddelen die salmeterol en fluticason bevatten. NL990012I2 (nl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB898920392A GB8920392D0 (en) 1989-09-08 1989-09-08 Medicaments
GB898923644A GB8923644D0 (en) 1989-10-20 1989-10-20 Medicaments
SG166294A SG166294G (en) 1989-09-08 1994-11-18 Inhalation medicaments for treating respiratory disorders

Publications (2)

Publication Number Publication Date
NL990012I1 NL990012I1 (nl) 1999-07-01
NL990012I2 true NL990012I2 (nl) 1999-09-01

Family

ID=27264677

Family Applications (1)

Application Number Title Priority Date Filing Date
NL990012C NL990012I2 (nl) 1989-09-08 1999-04-14 Geneesmiddelen die salmeterol en fluticason bevatten.

Country Status (20)

Country Link
EP (1) EP0416951B1 (OSRAM)
JP (1) JP3042867B2 (OSRAM)
AT (1) ATE99941T1 (OSRAM)
BE (1) BE1003053A3 (OSRAM)
CA (1) CA2024916C (OSRAM)
CH (1) CH680983C9 (OSRAM)
DE (2) DE19975040I2 (OSRAM)
DK (1) DK0416951T3 (OSRAM)
ES (1) ES2062392T3 (OSRAM)
FR (1) FR2651677B1 (OSRAM)
HK (1) HK18695A (OSRAM)
HU (1) HU211272A9 (OSRAM)
IE (1) IE65535B1 (OSRAM)
IL (1) IL95590A (OSRAM)
IT (1) IT1241996B (OSRAM)
LU (1) LU90392I2 (OSRAM)
NL (1) NL990012I2 (OSRAM)
NZ (1) NZ235221A (OSRAM)
PH (1) PH27594A (OSRAM)
SG (1) SG166294G (OSRAM)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270305A (en) 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
AU673660C (en) * 1991-12-18 2002-07-25 Astrazeneca Ab New combination of formoterol and budesonide
SE9703407D0 (sv) 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
PL200941B1 (pl) 1998-11-13 2009-02-27 Jagotec Ag Suchy proszkowy preparat inhalacyjny
GB9903759D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
GB9904919D0 (en) 1999-03-03 1999-04-28 Novartis Ag Organic compounds
FR2798290B1 (fr) 1999-09-11 2003-09-12 Glaxo Group Ltd Formulation pharmaceutique de propionate de fluticasone
ES2238334T3 (es) * 1999-12-24 2005-09-01 Glaxo Group Limited Formulacion farmaceutica en aerosol de salmeterol y propionato de fluticasona.
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
AU7576001A (en) 2000-08-05 2002-02-18 Glaxo Group Ltd 6.alpha., 9.alpha.-difluoro-17.alpha.-`(2-furanylcarboxyl) oxy]-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothioic acid s-fluoromethyl ester as an anti-inflammatory agent
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6787532B2 (en) 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
FI20002215A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
FI20002216A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit astman hoitoon
GB0103630D0 (en) * 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
DE60220887T2 (de) 2001-03-08 2008-02-28 Glaxo Group Ltd., Greenford Agonisten von beta-adrenorezeptoren
WO2002076933A1 (en) 2001-03-22 2002-10-03 Glaxo Group Limited Formailide derivatives as beta2-adrenoreceptor agonists
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
DK1383786T3 (da) 2001-04-30 2009-01-12 Glaxo Group Ltd Antiinflammatoriske 17-beta-carbothioatesterderivater af androstan med en cyklisk estergruppe i 17alfa-stilling
MXPA04002405A (es) 2001-09-14 2004-05-31 Glaxo Group Limetd Derivados de fenetanolamina para tratamiento de enfermedades respiratorias.
DE10202940A1 (de) 2002-01-24 2003-07-31 Sofotec Gmbh & Co Kg Patrone für einen Pulverinhalator
US7258118B2 (en) 2002-01-24 2007-08-21 Sofotec Gmbh & Co, Kg Pharmaceutical powder cartridge, and inhaler equipped with same
AU2003205855A1 (en) † 2002-02-04 2003-09-02 Glaxo Group Limited Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist
EP1757281A3 (en) * 2002-02-04 2009-07-15 Glaxo Group Limited Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist
CA2477714C (en) * 2002-03-04 2011-01-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg New cinnamic acid salts, processes for the preparation thereof and use thereof as medicament
GB0208609D0 (en) * 2002-04-13 2002-05-22 Glaxo Group Ltd Compositions
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
HRP20050611B1 (hr) 2002-12-12 2013-12-20 Takeda Gmbh Kombinacijski lijek
GB0303396D0 (en) 2003-02-14 2003-03-19 Glaxo Group Ltd Medicinal compounds
SE527069C2 (sv) 2003-06-19 2005-12-13 Mederio Ag Förfarande och anordning för administrering av läkemedelspulver
EP1658063B1 (en) 2003-08-06 2014-03-12 Galephar M/F Advantageous combinations for inhalation of nacystelyn and bronchodilators
AP2006003734A0 (en) * 2004-03-12 2006-10-31 Cipla Ltd Inhalation formulation
UA93031C2 (uk) 2004-07-16 2011-01-10 Алміралл, С.А. Інгалятор для порошкових медикаментів, фармацевтичний порошковий картридж для використання з інгалятором та спосіб використання інгалятора
AU2007338305B2 (en) 2006-12-22 2013-05-09 Astrazeneca Ab Inhalation device for drugs in powder form
CN101744792B (zh) * 2008-12-17 2013-04-17 张凯 氟替卡松丙酸酯和沙美特罗昔萘酸酯复方干粉吸入剂及其制备工艺
AR076807A1 (es) 2009-05-29 2011-07-06 Pearl Therapeutics Inc Composiciones metodos y sistemas para el suministro de dos o mas agentes activos mediante las vias respiratorias. metodo de preparacion composicion
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
CA2905542C (en) 2013-03-15 2022-05-03 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
BR112015027017A2 (pt) * 2013-04-29 2017-07-25 Sanofi Sa composições farmacêuticas inaláveis e dispositivos inaladores que contêm as mesmas

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2107715B (en) * 1981-10-19 1985-11-13 Glaxo Group Ltd Micronised beclomethasone dipropionate monohydrate and powder inhalation compositions containing it
ZW6584A1 (en) * 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
FR2588474B1 (fr) * 1985-10-16 1987-11-27 Cird Compositions synergetiques anti-inflammatoires a base d'un corticosteroide et d'un beta agoniste

Also Published As

Publication number Publication date
PH27594A (en) 1993-08-31
IL95590A0 (en) 1991-09-16
SG166294G (en) 1995-06-16
DE19975040I2 (de) 2006-07-13
DE69005951D1 (de) 1994-02-24
DK0416951T3 (da) 1994-02-14
FR2651677A1 (fr) 1991-03-15
IE65535B1 (en) 1995-11-01
IE903256A1 (en) 1991-03-13
JP3042867B2 (ja) 2000-05-22
IL95590A (en) 1996-06-18
EP0416951A1 (en) 1991-03-13
CH680983C9 (OSRAM) 2008-08-15
NL990012I1 (nl) 1999-07-01
ATE99941T1 (de) 1994-01-15
JPH03167120A (ja) 1991-07-19
FR2651677B1 (fr) 1993-08-06
LU90392I2 (fr) 1999-06-28
DE69005951T2 (de) 1994-05-26
CA2024916A1 (en) 1991-03-09
CH680983A5 (OSRAM) 1992-12-31
IT9048260A0 (it) 1990-09-07
NZ235221A (en) 1992-11-25
CA2024916C (en) 2002-07-09
EP0416951B1 (en) 1994-01-12
HU211272A9 (en) 1995-11-28
HK18695A (en) 1995-02-17
CH680983C1 (OSRAM) 2008-06-25
BE1003053A3 (fr) 1991-11-05
ES2062392T3 (es) 1994-12-16
IT9048260A1 (it) 1992-03-07
IT1241996B (it) 1994-02-02

Similar Documents

Publication Publication Date Title
NL990012I1 (nl) Geneesmiddelen die salmeterol en fluticason bevatten.
DE69002718D1 (de) Medikamente.
CA2093806A1 (en) Method of treating or preventing type 1 diabetes by oral administration of insulin
ATE515265T1 (de) Vitamin d und dessen analoge zur behandlung vom tumoren und anderen hyperproliferativen erkrankungen
CA2123909A1 (en) New combination of formoterol and budesonide
HU9202808D0 (en) Improvement of down-regulqtion of autoimmunic diseases by means of oral dosing of autoantigenes
ZA888461B (en) Azelastine-containing medicaments for application in the nose and/or at the eye
DE69200711D1 (de) Pharmazeutische Zusammensetzungen enthaltend Fluticasonpropionat und Oxikonazol oder dessen Salz zur lokalen Anwendung.
DE69004532D1 (de) Topisch anzuwendende Defibrotid enthaltende Arzneizubereitungen.
DE69918961D1 (de) Verbesserte inhalationspräparate
MY111155A (en) Medicaments
JPS6438027A (en) Remedy for cancer
RU93003454A (ru) Лекарственный препарат